Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism.
Patients with Laron-type dwarfism are clinically indistinguishable from those with isolated growth hormone (GH) deficiency, yet have high circulating GH concentrations associated with an inability to generate endogenous insulin-like growth factor I (IGF-I). Biosynthetic IGF-I was administered subcutaneously once daily for 3 to 10 months to 5 children with Laron-type dwarfism aged 3.3 to 14.5 years. There was a rapid stimulation of linear growth in body limbs, with a striking increase in head circumference, increased body weight, and a reduction in subcutaneous fat. Administration of IGF-I to patients with Laron-type dwarfism seems to have a beneficial effect on growth similar to that observed with long-term administration of GH in children with GH deficiency.
Institute of Paediatric and Adolescent Endocrinology, Children's Medical Centre, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel.
Z
Z
Laron
S
S
Anin
Y
Y
Klipper-Aurbach
B
B
Klinger
D000273:Adipose Tissue; D000293:Adolescent; D000886:Anthropometry; D002508:Cephalometry; D002648:Child; D002675:Child, Preschool; D004393:Dwarfism, Pituitary / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006128:Growth / Q000187:drug effects; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone